



Supplementary Figure 2. Kaplan-Meier estimates of PFS among patients with a high level of PVTT according to the treatment group (A) before and (B) after IPTW. Propensity scores of inverse probability of treatment weighting were computed using age, sex, the presence or absence of liver cirrhosis, esophageal or gastric varices, fibrosis-4 index, Child-Pugh score, serum levels of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II, the presence or absence of hepatic vein invasion of hepatocellular carcinoma, and the presence or absence of lymph node or extrahepatic metastasis. Atezo + bev, atezolizumab plus bevacizumab; PFS, progression-free survival; PVTT, portal vein tumor thrombosis; IPTW, inverse probability of treatment weighting.